A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ganciclovir (Ganciclovir)

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class · 5 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval2010-04-30
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$13.6M in CY2024 Part D spend28K claims · 17K beneficiaries · 329 plans surveyed

Lowest NADAC
$91.38/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$91.38
Across all dosage forms in distribution.
Highest NADAC
$91.38
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Ganciclovir used for?

Ganciclovir is a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Ganciclovir?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Ganciclovir?

Across 329 Part D plans, Ganciclovir averages $91.38/unit (NADAC). Lowest available: $91.38/unit. Highest in distribution: $91.38/unit.

Is Ganciclovir on the FDA shortage list?

No. Ganciclovir is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor1 alternative in D1
01
Valganciclovir
Brand: VALGANCICLOVIR
$1.44Lowest NADAC
11Generic mfrs
$41.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.